Related Experiment Video

Updated: Dec 30, 2025

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

25.3K

STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways

Fei Liu1, Hao Su1, Bo Liu1

  • 1Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.

International Journal of Molecular Sciences
|January 24, 2020
PubMed

Insights

Isosteviol sodium (STVNa) protects against cardiac hypertrophy by restoring mitochondrial function and reducing oxidative stress. This compound shows potential for treating heart conditions like cardiac hypertrophy.

Area of Science:

  • Cardiology
  • Mitochondrial Biology
  • Pharmacology

Background:

  • Cardiac hypertrophy is a significant contributor to heart failure.
  • Mitochondrial dysfunction is a hallmark of cardiac hypertrophy.
  • Isosteviol has demonstrated protective effects against myocardial ischemia-reperfusion injury.

Purpose of the Study:

  • To investigate the protective mechanisms of isosteviol sodium (STVNa) against isoproterenol (Iso)-induced cardiac hypertrophy.
  • To elucidate the role of STVNa in mitochondrial function and oxidative stress in cardiac hypertrophy.

Main Methods:

  • Utilized H9c2 cells and rat primary cardiomyocytes.
  • Induced cardiac hypertrophy using isoproterenol (Iso).
  • Assessed cell surface area, mitochondrial membrane potential (MMP), mitochondrial morphology, protein expression (Fis1, Drp1, Trx1, Prdx2), reactive oxygen species (ROS) levels, and histone deacetylase 4 (HDAC4) activity.

Main Results:

  • STVNa significantly inhibited cardiomyocyte hypertrophy.
  • STVNa restored MMP and mitochondrial integrity.
  • STVNa decreased Fis1 and Drp1 expression, reduced ROS levels, and upregulated Trx1 and Prdx2 expression.
  • STVNa restored nuclear HDAC4 activity.

Conclusions:

  • STVNa confers protection against isoproterenol-induced cardiac hypertrophy.
  • The protective effects are mediated through the Prdx2/ROS/Trx1 signaling pathway.
  • STVNa is a potential therapeutic agent for human cardiac hypertrophy.

Keywords:
ROScardiac hypertrophyisosteviol sodiumperoxiredoxinthioredoxin

More Related Videos

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

2.0K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.6K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
844
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
607
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
746
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
697